Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Biologic drug survival in Israeli psoriasis patients
Guy Shalom
, Arnon D. Cohen
, Michael Ziv
, Cohen Barak Eran
, Ilan Feldhamer
, Tamar Freud
, Eitan Berman
, Shirley Oren
,
Emmilia Hodak
,
Lev Pavlovsky
*
*
Corresponding author for this work
Dermatology
Soroka Medical Center
Ben-Gurion University of the Negev
Clalit Health Services
Emek Medical Center
Rabin Medical Center Israel
Research output
:
Contribution to journal
›
Article
›
peer-review
61
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Biologic drug survival in Israeli psoriasis patients'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acitretin
25%
Adalimumab
25%
Biological Drugs
100%
Biological Treatment
50%
Cyclosporine
25%
Demographic Variables
25%
Disease Duration
25%
Disease Severity
25%
Drug Survival
100%
Etanercept
25%
Female Sex
25%
Health Care Services
50%
High Survival
25%
Infliximab
25%
Israeli
100%
Metabolic Syndrome
25%
Methotrexate
50%
Moderate-to-severe Psoriasis
50%
Multivariate Analysis
25%
Naivety
50%
Past Exposure
25%
Predictive Factors
25%
Psoriasis
25%
Psoriasis Disease
100%
Psoriasis Treatment
25%
Psoriatic Arthritis
25%
Retention Rate
25%
Significant Predictors
25%
Survival Analysis
25%
Survival Rate
50%
Systemic Treatment
75%
Third-line Therapy
25%
Treatment Exposure
25%
Tumour Necrosis Factor Inhibitor (TNFi)
25%
Ustekinumab
75%
Medicine and Dentistry
Adalimumab
20%
Biological Product
60%
Cyclosporine
20%
Disease Duration
20%
Disease Severity
20%
Etanercept
20%
Etretin
20%
Health Service
40%
Infliximab
20%
Metabolic Syndrome
20%
Methotrexate
40%
Multivariate Analysis
20%
Psoriasis
100%
Psoriatic Arthritis
20%
Survival Analysis
20%
Survival Rate
40%
Systemic Therapy
60%
TNF Inhibitor
20%
Ustekinumab
60%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
20%
Biological Product
60%
Ciclosporin
20%
Disease Duration
20%
Disease Severity
20%
Etanercept
20%
Etretin
20%
Infliximab
20%
Metabolic Syndrome X
20%
Methotrexate
40%
Psoriasis
100%
Psoriatic Arthritis
20%
Survival Rate
40%
Systemic Treatment
60%
Tumor Necrosis Factor Inhibitor
20%
Ustekinumab
60%